Compare FLNT & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNT | CUE |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.1M | 124.5M |
| IPO Year | 2009 | 2017 |
| Metric | FLNT | CUE |
|---|---|---|
| Price | $3.73 | $37.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.50 | ★ $120.00 |
| AVG Volume (30 Days) | ★ 224.3K | 94.1K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.67 | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $208,764,000.00 | $27,466,000.00 |
| Revenue This Year | $5.89 | N/A |
| Revenue Next Year | $12.62 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $1.70 | $0.17 |
| 52 Week High | $4.15 | $41.42 |
| Indicator | FLNT | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 61.99 | 67.34 |
| Support Level | $2.95 | $0.24 |
| Resistance Level | $4.03 | $41.42 |
| Average True Range (ATR) | 0.28 | 4.56 |
| MACD | 0.02 | 0.74 |
| Stochastic Oscillator | 66.20 | 59.71 |
Fluent Inc is a commerce media solutions provider that connects brands with engaged consumers by leveraging diverse advertising inventory, robust first-party data, and proprietary machine learning. The company mainly delivers customer acquisition services through scalable digital marketing campaigns, linking advertisers with targeted audiences. It reaches consumers through its Commerce Media Solutions, which integrate targeted advertising into e-commerce and digital media transaction flows on partner websites and mobile applications, as well as through its owned and operated digital media properties. The company operates in the United States, which generates the majority of its revenue, along with international markets.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.